These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 17706139)

  • 1. [Effects of AKT protein kinase activation on biologic behavior of diffuse large B cell lymphoma cells].
    Zhang TC; Zhou XY; Yu BH; Zhang TM; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2007 May; 36(5):318-23. PubMed ID: 17706139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on PI3K inhibitor LY294002 for chemotherapeutic sensitization in diffuse large B cell lymphoma cell lines].
    Zhang TC; Chu HJ; Zhao JQ; Zhou XY; Shi DR
    Zhonghua Xue Ye Xue Za Zhi; 2010 Oct; 31(10):671-4. PubMed ID: 21223717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of the PIK3CA gene in diffuse large B cell lymphoma.
    Baohua Y; Xiaoyan Z; Tiecheng Z; Tao Q; Daren S
    Diagn Mol Pathol; 2008 Sep; 17(3):159-65. PubMed ID: 18382359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
    Uddin S; Hussain AR; Siraj AK; Manogaran PS; Al-Jomah NA; Moorji A; Atizado V; Al-Dayel F; Belgaumi A; El-Solh H; Ezzat A; Bavi P; Al-Kuraya KS
    Blood; 2006 Dec; 108(13):4178-86. PubMed ID: 16946303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.
    Zhao MY; Auerbach A; D'Costa AM; Rapoport AP; Burger AM; Sausville EA; Stass SA; Jiang F; Sands AM; Aguilera N; Zhao XF
    Clin Cancer Res; 2009 Mar; 15(5):1708-20. PubMed ID: 19223503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Mills GB; Younes A
    Br J Haematol; 2006 Feb; 132(4):503-11. PubMed ID: 16412023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-9 promotes cell survival and drug resistance in diffuse large B-cell lymphoma.
    Lv X; Feng L; Ge X; Lu K; Wang X
    J Exp Clin Cancer Res; 2016 Jul; 35(1):106. PubMed ID: 27364124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Telomerase activity,PI3K/AKT signaling pathway and cellular biological behavior in HeLa cell line].
    Yu XX; Shi YA; Zhang LH; Wang YS; Wu S
    Zhonghua Bing Li Xue Za Zhi; 2008 May; 37(5):323-7. PubMed ID: 18956651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.
    Uddin S; Hussain AR; Al-Hussein KA; Manogaran PS; Wickrema A; Gutierrez MI; Bhatia KG
    Clin Cancer Res; 2005 Apr; 11(8):3102-8. PubMed ID: 15837766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Activation and clinicopathologic significance of AKT/mTOR signaling pathway in diffuse large B-cell lymphoma].
    Yu BH; Zhou XY; Xiao XY; Yan SY; Qin T; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):35-41. PubMed ID: 19489223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose human insulin and insulin glargine promote T24 bladder cancer cell proliferation via PI3K-independent activation of Akt.
    Liu S; Li Y; Lin T; Fan X; Liang Y; Heemann U
    Diabetes Res Clin Pract; 2011 Feb; 91(2):177-82. PubMed ID: 21129803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc.
    Cui W; Zheng S; Li X; Ma Y; Sang W; Liu M; Zhang W; Zhou X
    Tumour Biol; 2016 Sep; 37(9):12767-12777. PubMed ID: 27448819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [High D-glucose alters PI3K and Akt signaling and leads to endothelial cell migration, proliferation and angiogenesis dysfunction].
    Yu P; Yu DM; Qi JC; Wang J; Zhang QM; Zhang JY; Tang YZ; Xing QL; Li MZ
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3425-30. PubMed ID: 17313857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma.
    Zang C; Eucker J; Liu H; Coordes A; Lenarz M; Possinger K; Scholz CW
    Leuk Lymphoma; 2014 Feb; 55(2):425-34. PubMed ID: 23721513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.
    Semba S; Itoh N; Ito M; Harada M; Yamakawa M
    Clin Cancer Res; 2002 Jun; 8(6):1957-63. PubMed ID: 12060641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reversal effect of PI-3K/Akt pathway inhibitor LY294002 on multidrug resistance of ovarian cancer cell line A2780/Taxol].
    Shi XY; Cai XJ; Lei JX; Cao FJ; Pan DF; Chen P
    Ai Zheng; 2008 Apr; 27(4):343-7. PubMed ID: 18423117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.
    Wang J; Xu-Monette ZY; Jabbar KJ; Shen Q; Manyam GC; Tzankov A; Visco C; Wang J; Montes-Moreno S; Dybkær K; Tam W; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Ferreri AJM; Wang S; Møller MB; Piris MA; Medeiros LJ; Li Y; Pham LV; Young KH
    Am J Pathol; 2017 Aug; 187(8):1700-1716. PubMed ID: 28627414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells.
    Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H
    Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.